Article

Novel Drug Bests Tagrisso in Heavily Pretreated Lung Cancer

Author(s):

More patients with pretreated non-small cell lung cancer saw their disease disappear with abivertinib compared to Tagrisso.

Long-term data consisting of more than three years of follow-up, showed that many patients with heavily pretreated non-small cell lung cancer (NSCLC) saw their cancer shrink — or even disappear in some cases — when given the novel drug abivertinib.

Findings showed that of the 209 patients who responded to abivertinib, the overall response rate (the percentage of patients whose disease decreased as a result of treatment) was 56.5% (118 patients). This included 11 patients (5.3%) who had a complete response, meaning that clinicians could no longer detect cancer in these patients.

Only 0.5% of patients given Tagrisso (osimertinib) experienced a complete response, though the overall response rate for Tagrisso was comparable, according to a company-issued press release.

On average, patients lived for 28.2 months after receiving treatment with abivertinib, a novel EGFR-TKI therapy, compared to 26.8 months for those given Tagrisso.

Abivertinib is different from Tagrisso (another EGFR-TKI drug) because it may be able to overcome resistance to these types of drugs, which occurs in approximately 60% of patients who take EGFR-TKIs, according to data published in Clinical Cancer Research.

READ MORE: Targeted Therapy Advanced in Lung Cancer Space Over Past 2 Decades ‘Simply Remarkable’

Considering these findings, which are based off a clinical trial conducted in China, the drug’s manufacturer, Sorrento Therapeutics, plans on submitting a new-drug application to the Food and Drug Administration, according to the release.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out